156 related articles for article (PubMed ID: 19889117)
1. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.
Douglass JA; Carroll K; Voskamp A; Bourke P; Wei A; O'Hehir RE
Allergy; 2010 Jul; 65(7):926-7. PubMed ID: 19889117
[No Abstract] [Full Text] [Related]
2. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE.
Kontou-Fili K; Filis CI; Voulgari C; Panayiotidis PG
Ann Allergy Asthma Immunol; 2010 Jun; 104(6):537-9. PubMed ID: 20568389
[No Abstract] [Full Text] [Related]
3. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
Carter MC; Robyn JA; Bressler PB; Walker JC; Shapiro GG; Metcalfe DD
J Allergy Clin Immunol; 2007 Jun; 119(6):1550-1. PubMed ID: 17481708
[No Abstract] [Full Text] [Related]
4. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
[No Abstract] [Full Text] [Related]
6. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab.
Bell MC; Jackson DJ
Ann Allergy Asthma Immunol; 2012 May; 108(5):383-4. PubMed ID: 22541416
[No Abstract] [Full Text] [Related]
7. Mastocytosis and insect venom allergy.
Bonadonna P; Zanotti R; Müller U
Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):347-53. PubMed ID: 20485157
[TBL] [Abstract][Full Text] [Related]
8. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.
Constantine GM; Bressler PB; Petroni D; Metcalfe DD; Carter MC
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1314-1316. PubMed ID: 30149096
[No Abstract] [Full Text] [Related]
9. Successful treatment of idiopathic anaphylaxis in an adolescent.
Pitt TJ; Cisneros N; Kalicinsky C; Becker AB
J Allergy Clin Immunol; 2010 Aug; 126(2):415-6; author reply 416. PubMed ID: 20624653
[No Abstract] [Full Text] [Related]
10. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab.
Schulze J; Rose M; Zielen S
Allergy; 2007 Aug; 62(8):963-4. PubMed ID: 17484729
[No Abstract] [Full Text] [Related]
11. Idiopathic anaphylaxis successfully treated with omalizumab.
Jones JD; Marney SR; Fahrenholz JM
Ann Allergy Asthma Immunol; 2008 Nov; 101(5):550-1. PubMed ID: 19055211
[No Abstract] [Full Text] [Related]
12. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis.
Kontou-Fili K; Filis CI
Allergy; 2009 Sep; 64(9):1384-5. PubMed ID: 19432937
[No Abstract] [Full Text] [Related]
13. Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study).
Distler M; Maul JT; Steiner UC; Jandus P; Kolios AGA; Murer C; Graf N; Seebach JD; Pichler WJ; Navarini AA; French LE; Helbling A; Schmid-Grendelmeier P
Dermatology; 2020; 236(6):529-539. PubMed ID: 31958790
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM).
McComish JS; Slade CA; Buizen L; Paul SK; Chatelier JW; Unglik G; Nicholls KA; Spriggs K; Chan SS; Godsell J; Auyeung P; Tan ZH; DeLuca J; Patel M; Kuek LE; Tran Y; Kern JS; Scardamaglia L; Varigos GA; Juneja S; Grabek JA; Christie M; Mackay GA; Douglass JA
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2248-2250.e3. PubMed ID: 37088371
[No Abstract] [Full Text] [Related]
15. Recurrent syncope and anaphylaxis as presentation of systemic mastocytosis in a pediatric patient: case report and literature review.
Shaffer HC; Parsons DJ; Peden DB; Morrell D
J Am Acad Dermatol; 2006 May; 54(5 Suppl):S210-3. PubMed ID: 16631942
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab in idiopathic anaphylaxis.
Warrier P; Casale TB
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):257-8. PubMed ID: 19354075
[No Abstract] [Full Text] [Related]
17. Shortness of breath, syncope, and cardiac arrest caused by systemic mastocytosis.
Rohr SM; Rich MW; Silver KH
Ann Emerg Med; 2005 Jun; 45(6):592-4. PubMed ID: 15940090
[TBL] [Abstract][Full Text] [Related]
18. Anaphylaxis: a review of 601 cases.
Webb LM; Lieberman P
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):39-43. PubMed ID: 16892779
[TBL] [Abstract][Full Text] [Related]
19. IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis.
Matito A; Bartolomé-Zavala B; Alvarez-Twose I; Sánchez-Matas I; Escribano L
Allergy; 2010 Aug; 65(8):1058-9. PubMed ID: 20002662
[No Abstract] [Full Text] [Related]
20. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
